112 related articles for article (PubMed ID: 8106287)
1. Inhibition of catabolic pathway of 5-fluorouracil by 3-cyano-2,6-dihydroxypyridine in human lung cancer tissues.
Okayasu T; Sugiyama K; Miyauchi S
Jpn J Cancer Res; 1994 Jan; 85(1):101-5. PubMed ID: 8106287
[TBL] [Abstract][Full Text] [Related]
2. 3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase.
Tatsumi K; Yamauchi T; Kiyono K; Kishi K; Yanagihara Y; Imaoka T; Kawaguchi T; Kubo M
J Biochem; 1993 Dec; 114(6):912-8. PubMed ID: 8138551
[TBL] [Abstract][Full Text] [Related]
3. [Metabolic characteristics and antitumor activity of BOF-A2, a new 5-fluorouracil derivative].
Shirasaka T; Fukushima M; Shimamoto Y; Kimura Y; Ohshimo H; Imaoka T; Kimura A; Utsunomiya T; Fujii S
Gan To Kagaku Ryoho; 1990 May; 17(5):1051-8. PubMed ID: 2334171
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of BOF-A2, a new 5-fluorouracil derivative.
Fujii S; Fukushima M; Shimamoto Y; Ohshimo H; Imaoka T; Shirasaka T
Jpn J Cancer Res; 1989 Feb; 80(2):173-81. PubMed ID: 2498252
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of 5-fluorouracil in various human normal and tumor tissues.
Maehara Y; Nagayama S; Okazaki H; Nakamura H; Shirasaka T; Fujii S
Gan; 1981 Dec; 72(6):824-7. PubMed ID: 6176492
[TBL] [Abstract][Full Text] [Related]
6. The inhibitory action of BOF-A2, a 5-fluorouracil derivative, on squamous cell carcinoma.
Yoneda K; Yamamoto T; Ueta E; Osaki T
Cancer Lett; 1999 Mar; 137(1):17-25. PubMed ID: 10376790
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. A multi-center phase II study.
Nakai Y; Furuse K; Ohta M; Yamaguchi Y; Fujii M; Asakawa M; Fukuoka M; Yoshida K; Niitani H
Acta Oncol; 1994; 33(5):523-6. PubMed ID: 7917366
[TBL] [Abstract][Full Text] [Related]
8. Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluorouracil levels.
Miyauchi S; Imaoka T; Utsunomiya T; Hayashi K; Kubo M; Kawaguchi T; Matsui Y
Jpn J Cancer Res; 1994 Jun; 85(6):665-8. PubMed ID: 8063621
[TBL] [Abstract][Full Text] [Related]
9. [BOF-A1 and BOF-A2, new 5-FU degradation-inhibitory agents].
Fujii S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2244-50. PubMed ID: 2955745
[TBL] [Abstract][Full Text] [Related]
10. Leukopenia-inducing effect of a combination of a new 5-fluorouracil (5-FU)-derived drug, BOF-A2 (emitefur), with other 5-FU-derived drugs or BV-araU (sorivudine) in rats.
Miyauchi S; Imaoka T; Okada T; Motoyama M; Kawaguchi T; Akiyama H; Odomi M
Jpn J Pharmacol; 1996 Feb; 70(2):139-48. PubMed ID: 8866751
[TBL] [Abstract][Full Text] [Related]
11. Comparison of pyrimidine nucleotide synthetic enzymes involved in 5-fluorouracil metabolism between human adenocarcinomas and squamous cell carcinomas.
Maehara Y; Moriguchi S; Emi Y; Watanabe A; Kohnoe S; Tsujitani S; Sugimachi K
Cancer; 1990 Jul; 66(1):156-61. PubMed ID: 2162241
[TBL] [Abstract][Full Text] [Related]
12. Comparative studies on the metabolism of new fluorinated pyrimidine drugs in the liver by in vivo 19F magnetic resonance spectroscopic observation.
Harada M; Nishitani H; Koga K; Miura I; Kimura A
Jpn J Cancer Res; 1993 Feb; 84(2):197-202. PubMed ID: 8463136
[TBL] [Abstract][Full Text] [Related]
13. [Estimation of pathways of 5-fluorouracil anabolism in human cancer cells in vitro and in vivo].
Fukushima M; Nomura H; Murakami Y; Shirasaka T; Aiba K
Gan To Kagaku Ryoho; 1996 May; 23(6):721-31. PubMed ID: 8645024
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study on the permeability of FT-207 and 5-FU in primary lung cancer].
Aogauchi R; Tsubota N; Yamashita C; Yoshikawa K; Ishii N; Nakamura K
Gan To Kagaku Ryoho; 1985 Jan; 12(1):105-10. PubMed ID: 3917651
[TBL] [Abstract][Full Text] [Related]
15. Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcomas in rats.
Fujii S; Shimamoto Y; Ohshimo H; Imaoka T; Motoyama M; Fukushima M; Shirasaka T
Jpn J Cancer Res; 1989 Feb; 80(2):167-72. PubMed ID: 2498251
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic modulation of plasma 5-fluorouracil concentrations to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil.
Fujii S; Fukushima M; Shimamoto Y; Shirasaka T
Jpn J Cancer Res; 1989 Jun; 80(6):509-12. PubMed ID: 2503471
[TBL] [Abstract][Full Text] [Related]
17. [5-FU concentration in blood and tissue of patients with primary lung cancer after oral administration of UFT].
Oiwa T; Saito H
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):525-30. PubMed ID: 3082289
[TBL] [Abstract][Full Text] [Related]
18. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T
Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586
[TBL] [Abstract][Full Text] [Related]
19. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts.
Tatsumi K; Fukushima M; Shirasaka T; Fujii S
Jpn J Cancer Res; 1987 Jul; 78(7):748-55. PubMed ID: 3114201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
